{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:16Z","timestamp":1793916016550,"version":"4.8.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.seminoncol.2025.152411","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T21:11:14Z","timestamp":1757020274000},"page":"152411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer"],"prefix":"10.1016","volume":"52","author":[{"given":"Daniel A.","family":"Guirguis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariha","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Alabd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Mortada Shehata","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartick","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-2929","authenticated-orcid":false,"given":"Manoj K","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seminoncol.2025.152411_bib0001","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0029-1196806","article-title":"Ueber die z\u00fcchtung der Erysipelkokken auf k\u00fcnstlichem n\u00e4hrboden und ihre \u00fcbertragbarkeit auf den Menschen","volume":"8","author":"Fehleisen","year":"1882","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0002","first-page":"137","article-title":"Aus der sitzung der medicinischen Section vom 13 November 1867","volume":"5","author":"Busch","year":"1868","journal-title":"Berl Klin Wochenschr"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0003","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/bbug.1.2.11248","article-title":"Bacteria as tumor therapeutics?","volume":"1","author":"Oelschlaeger","year":"2010","journal-title":"Bioeng Bugs"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0004","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0005","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthopaed J"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3181\/00379727-26-4143","article-title":"On the pathological relations between cancer and tuberculosis","volume":"26","author":"Pearl","year":"1928","journal-title":"Proceed Soc Exp Biol Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer: a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0009","doi-asserted-by":"crossref","unstructured":"J. Quesada, The role of interferon alpha in the treatment of hairy cell leukemia (HCL), Clinical aspects of interferons, Boston, MA: Springer; 1988, pp. 121-126.","DOI":"10.1007\/978-1-4613-1737-1_9"},{"issue":"3","key":"10.1016\/j.seminoncol.2025.152411_bib0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V65.3.644.644","article-title":"Treatment of hairy cell leukemia with recombinant alpha 2 interferon","volume":"65","author":"Ratain","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0011","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0012","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"New Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0013","first-page":"381","article-title":"Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma","volume":"84","author":"Mansh","year":"2011","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0015","first-page":"180","article-title":"Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0016","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"Pd-1\/pd-l1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152411_bib0018","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.seminoncol.2015.05.005","article-title":"Adoptive Cell Therapy\u2013Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors","volume":"42","author":"Feldman","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0019","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"New Engl J Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0020","first-page":"126","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science (1979)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0022","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proceed Natl Acad Sci"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0023","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0024","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Ca Therapeut"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0026","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Translat Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0028","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0029","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BS9.0000000000000173","article-title":"CAR-T cell therapy: where are we now, and where are we heading?","volume":"5","author":"Wang","year":"2023","journal-title":"Blood Science"},{"issue":"1","key":"10.1016\/j.seminoncol.2025.152411_bib0030","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0032","doi-asserted-by":"crossref","first-page":"210","DOI":"10.32074\/1591-951X-167","article-title":"Malignant epithelial\/exocrine tumors of the pancreas","volume":"112","author":"Luchini","year":"2020","journal-title":"Pathologica"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0033","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0034","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/PAS.0000000000000533","article-title":"A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"10.1016\/j.seminoncol.2025.152411_bib0035","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/cancers13194932","article-title":"The Heterogeneity of the Tumor Microenvironment as Essential Determinant of Development, Progression and Therapy Response of Pancreatic Cancer","volume":"13","author":"Group Young Researchers In Inflammatory Carcinogenesis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0036","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/07435800.2010.525085","article-title":"Pancreatic neuroendocrine tumors","volume":"36","author":"Batcher","year":"2011","journal-title":"Endocr Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0037","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2002.08.017","article-title":"Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review","volume":"20","author":"Berinstein","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0038","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0039","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0040","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Ca Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0041","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Modern Pathol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0042","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Hassan","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0043","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0044","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/1097-0142(197302)31:2<324::AID-CNCR2820310208>3.0.CO;2-Y","article-title":"Carcinoembryonic antigen (CEA) in the diagnosis of pancreatic cancer","volume":"31","author":"Ona","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ajcp\/82.5.535","article-title":"Immunohistochemical observations of carcinoembryonic antigen (CEA) and CEA-related substances in normal and neoplastic pancreas: pitfalls and caveats in CEA immunohistochemistry","volume":"82","author":"Tsutsumi","year":"1984","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0046","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/gut.21.8.656","article-title":"Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease","volume":"21","author":"Carr-Locke","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/90.1.17","article-title":"Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma","volume":"90","author":"Albers","year":"1988","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0048","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0049","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.molmed.2019.10.003","article-title":"Microbe\u2013MUC1 crosstalk in cancer-associated infections","volume":"26","author":"Bose","year":"2020","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110888","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0051","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.3390\/ijms22126567","article-title":"MUC1: structure, function, and clinic application in epithelial cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0052","first-page":"161","article-title":"Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients","volume":"18","author":"Tanaka","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0053","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12935-024-03320-6","article-title":"Significance of PSCA as a novel prognostic marker and therapeutic target for cancer","volume":"24","author":"Nayerpour Dizaj","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0054","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/0008-5472.CAN-07-6463","article-title":"Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA","volume":"68","author":"Sagiv","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/B:HIJO.0000032357.16261.c5","article-title":"Tumour biological aspects of CD24, a mucin-like adhesion molecule","volume":"35","author":"Kristiansen","year":"2004","journal-title":"J Mol Histol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0056","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.4049\/jimmunol.166.9.5567","article-title":"CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains\/rafts-mediated signaling system","volume":"166","author":"Suzuki","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0057","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s004010050442","article-title":"CD24, a glycosylphosphatidylinositol-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors","volume":"91","author":"Poncet","year":"1996","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0058","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1159\/000079824","article-title":"Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades","volume":"4","author":"Jacob","year":"2004","journal-title":"Pancreatology"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0059","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0092-8674(86)90779-8","article-title":"Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185","volume":"45","author":"Bargmann","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0061","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer\u2013beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0062","article-title":"Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2","volume":"611","author":"Tojjari","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0063","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0064","article-title":"Research progress of pancreas-related microorganisms and pancreatic cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0065","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.18632\/oncotarget.3228","article-title":"CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer","volume":"6","author":"Nomura","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0066","doi-asserted-by":"crossref","unstructured":"M.R. Bowman, M. Crimmins, J. Yetz-Aldape, R. Kriz, K. Kelleher, S. Herrmann, The cloning of CD70 and its identification as the ligand for CD27, J Immunol (Baltimore, Md.: 1950), 152 (1994) 1756-1761.","DOI":"10.4049\/jimmunol.152.4.1756"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0067","doi-asserted-by":"crossref","unstructured":"R.Q. HintZen, S.M. Lens, M.P. Beckmann, R. Goodwin, D. Lynch, R. Van Lier, Characterization of the human CD27 ligand, a novel member of the TNF gene family, J Immunol (Baltimore, Md.: 1950), 152 (1994) 1762-1773.","DOI":"10.4049\/jimmunol.152.4.1762"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0068","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0069","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/cancers15030601","article-title":"Tumor growth suppression of pancreatic cancer orthotopic xenograft model by CEA-targeting CAR-T cells","volume":"15","author":"Sato","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0092-8674(88)90184-5","article-title":"Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene","volume":"54","author":"Muller","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0071","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0072","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proceed Natl Acad Sci"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0073","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0074","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer (1965)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/cancers10090277","article-title":"The impact of mesothelin in the ovarian cancer tumor microenvironment","volume":"10","author":"Hilliard","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0076","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0077","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0078","doi-asserted-by":"crossref","first-page":"8579","DOI":"10.1245\/s10434-021-10507-y","article-title":"Mesothelin expression is correlated with chemoresistance in stage IV colorectal cancer","volume":"28","author":"Nagata","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0079","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","article-title":"Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3","volume":"6","author":"Bharadwaj","year":"2008","journal-title":"Mol Ca Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0080","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0081","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells","volume":"6","author":"Uehara","year":"2008","journal-title":"Mol Ca Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0082","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers14061550","article-title":"Mesothelin: an immunotherapeutic target beyond solid tumors","volume":"14","author":"Faust","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0083","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1158\/1535-7163.MCT-22-0073","article-title":"Development of highly effective anti-mesothelin hYP218 chimeric antigen receptor T cells with increased tumor infiltration and persistence for treating solid tumors","volume":"21","author":"Tomar","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0084","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10555-015-9549-1","article-title":"Genetically engineered mucin mouse models for inflammation and cancer","volume":"34","author":"Joshi","year":"2015","journal-title":"Ca Metastas Rev"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0085","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1074\/jbc.M011248200","article-title":"Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland","volume":"276","author":"Schroeder","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0086","first-page":"28","article-title":"Distinct evolution of the human carcinoma-associated transmembrane mucins","volume":"373","author":"Duraisamy","year":"2006","journal-title":"MUC1, MUC4 AND MUC16, Gene"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0087","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ncb1661","article-title":"MUC1 oncoprotein activates the i\u03bab kinase \u03b2 complex and constitutive NF-\u03bab signalling","volume":"9","author":"Ahmad","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0088","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.3748\/wjg.v20.i20.6123","article-title":"Clinicopathological utility of sialoglycoconjugates in diagnosing and treating colorectal cancer","volume":"20","author":"Inagaki","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0089","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1021\/acs.jproteome.7b00246","article-title":"Glucose limitation alters glutamine metabolism in MUC1-overexpressing pancreatic cancer cells","volume":"16","author":"Gebregiworgis","year":"2017","journal-title":"J Proteome Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0090","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.3390\/molecules28207033","article-title":"Mucin glycans: a target for cancer therapy","volume":"28","author":"Sun","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0091","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bjc.6603494","article-title":"EpCAM (CD326) finding its role in cancer","volume":"96","author":"Baeuerle","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0092","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1158\/0008-5472.CAN-09-0654","article-title":"The emerging role of EpCAM in cancer and stem cell signaling","volume":"69","author":"Munz","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0093","doi-asserted-by":"crossref","unstructured":"L. Keller, S. Werner, K. Pantel, Biology and clinical relevance of EpCAM, cell stress, 3 (2019) 165.","DOI":"10.15698\/cst2019.06.188"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0094","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/annonc\/mdr625","article-title":"Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer","volume":"23","author":"Schmidt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0095","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mds178","article-title":"Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II\/III study comparing paracentesis plus catumaxomab with paracentesis alone","volume":"23","author":"Wimberger","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0096","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0097","doi-asserted-by":"crossref","first-page":"eadg9721","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0098","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1096\/fj.07-8319com","article-title":"Formation of tight junction: determinants of homophilic interaction between classic claudins","volume":"22","author":"Piorntek","year":"2008","journal-title":"FASEB J"},{"issue":"21","key":"10.1016\/j.seminoncol.2025.152411_bib0099","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.gene.2011.04.007","article-title":"Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals","volume":"481","author":"T\u00fcreci","year":"2011","journal-title":"Gene"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0101","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Ca Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1325860","article-title":"Complete remission of advanced pancreatic cancer induced by claudin18. 2-targeted CAR-T cell therapy: a case report","volume":"15","author":"Zhong","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0103","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1038\/s41598-019-44874-0","article-title":"Targeting CLDN18. 2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0104","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.mpa.0000173459.81193.4d","article-title":"Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer","volume":"31","author":"Wente","year":"2005","journal-title":"Pancreas"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0105","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-shelf prostate stem cell antigen\u2013directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0106","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s00018-012-1055-9","article-title":"CD24 controls src\/STAT3 activity in human tumors","volume":"69","author":"Bretz","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0107","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1570163814666170818125036","article-title":"Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy","volume":"18","author":"Eyvazi","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0108","first-page":"2890","article-title":"Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray","volume":"62","author":"Han","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4049\/jimmunol.170.1.252","article-title":"Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells","volume":"170","author":"Taguchi","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0110","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0111","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.pan.2021.01.013","article-title":"Clinical relevance of CD70 expression in resected pancreatic cancer: prognostic value and therapeutic potential","volume":"21","author":"Nakamura","year":"2021","journal-title":"Pancreatol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1531294","article-title":"A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0113","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.fsi.2017.12.021","article-title":"Olive flounder CD276 (B7-H3) a coinhibitory molecule for T cells: responses during viral hemorrhagic septicemia virus (VHSV) stimulation","volume":"73","author":"Hwang","year":"2018","journal-title":"Fish Shellfish Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0114","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Ca Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0115","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Am J Clin Exp Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117252","article-title":"Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies","volume":"178","author":"Lin","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0119","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/cancers14133230","article-title":"Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0121","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1158\/1538-7445.AM2025-4805","article-title":"Dual-target CAR-T strategy for MSLN and CLDN18. 2: advancing cancer treatment with superior efficacy and safety","volume":"85","author":"Yang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0122","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0646-9","article-title":"Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy","volume":"11","author":"Zhang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0124","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","article-title":"Enhancing the potency and specificity of engineered T cells for cancer treatment","volume":"8","author":"Sukumaran","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0125","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0126","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","author":"Lai","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0127","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0128","article-title":"Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: current research and future perspective","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0129","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1053\/j.gastro.2020.11.044","article-title":"Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice","volume":"160","author":"Peran","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/cancers12071978","article-title":"Depletion of macrophages improves therapeutic response to gemcitabine in murine pancreas cancer","volume":"12","author":"Buchholz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0131","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ebiom.2019.01.037","article-title":"Cytosolic 5\u2032-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites","volume":"40","author":"Patzak","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0132","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/0008-5472.CAN-03-1860","article-title":"Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1\u03b2","volume":"64","author":"M\u00fcerk\u00f6ster","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0133","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ijc.23703","article-title":"Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma\u2014Epigenetic downregulation of caspases","volume":"123","author":"M\u00fcerk\u00f6ster","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0134","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/cancers13194932","article-title":"The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer","volume":"13","author":"Carcinogenesis","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0135","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","article-title":"CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03bab\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer","volume":"31","author":"Sun","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0136","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0137","first-page":"154","article-title":"Targeting fibroblast activation protein in tumor stroma with","volume":"2","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0138","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0139","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omto.2020.05.009","article-title":"Engineering chimeric antigen receptor T cells against immune checkpoint inhibitors PD-1\/PD-L1 for treating pancreatic cancer","volume":"17","author":"Yang","year":"2020","journal-title":"Mol Ther-Oncolyt"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0141","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0142","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115740","article-title":"Co-expression of IL-4\/IL-15-based inverted cytokine receptor in CAR-T cells overcomes IL-4 signaling in immunosuppressive pancreatic tumor microenvironment","volume":"168","author":"Zhou","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.seminoncol.2025.152411_bib0143","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0144","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.seminoncol.2025.152411_bib0145","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/blood.2019004500","article-title":"Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity","volume":"136","author":"Fultang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0146","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Diff"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0147","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and tgf\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0148","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4+ 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0149","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3892\/ol.2023.13867","article-title":"Combination of CAR\u2011T cell therapy and radiotherapy: opportunities and challenges in solid tumors","volume":"26","author":"Zhong","year":"2023","journal-title":"Oncol Lett"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0150","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0151","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1158\/2326-6066.CIR-22-0840","article-title":"Tumor-targeted nonablative radiation promotes solid tumor CAR T-cell therapy efficacy","volume":"11","author":"Quach","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0152","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijrobp.2018.10.009","article-title":"An antitumor immune response is evoked by partial-volume single-dose radiation in 2 murine models","volume":"103","author":"Markovsky","year":"2019","journal-title":"Int J Radiat Oncol* Biol* Phys"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0153","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014Challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0154","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","article-title":"The potential of CAR T cell therapy in pancreatic cancer","volume":"9","author":"Akce","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.627549","article-title":"Strategies for dodging the obstacles in CAR T cell therapy","volume":"11","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0156","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0157","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jso.24627","article-title":"CAR T-cell therapy for pancreatic cancer","volume":"116","author":"DeSelm","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0158","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0159","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0160","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0161","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0162","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3389\/fphar.2014.00254","article-title":"Improving the safety of cell therapy products by suicide gene transfer","volume":"5","author":"Jones","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.seminoncol.2025.152411_bib0163","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775425001034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:55:26Z","timestamp":1763690126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775425001034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0093775425001034"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152411","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152411"}}